Study Highlights How Patient-Preference Data and Tools Can Influence US Food and Drug Administration Regulatory Evaluation of Devices
Source
Surgical Endoscopy
Link
Incorporating Patient-Preference Evidence Into Regulatory Decision-Making
Description of Case Study
The US Food and Drug Administration’s (FDA) Center for Devices and Radiological Health conducted one of the first quantitative patient-preference studies designed specifically to inform regulatory decision-making for medical devices. Using a discrete-choice experiment with 540 adults with obesity, the study quantified how patients weighed benefits (e.g., amount and duration of weight loss) against risks (e.g., mortality risk, side effects) and other device attributes. The resulting preference data were used to develop a decision-support tool that estimates the minimum clinical benefit patients require to accept specific risks and the maximum level of risk they are willing to tolerate, enabling FDA reviewers to incorporate patient preferences into benefit-risk assessments for weight-loss devices. The approach has informed FDA evaluations of device effectiveness and provides a framework that can be applied across other medical products.
Quick Facts Organization name: FDA CDRH |
Product Type(s)
medical device:
- therapeutic device
Product Medical Specialty Area(s)
- gastroenterology and urology
Stakeholders
- medtech company: internal discovery/research and development teams
- medtech company: internal regulatory affairs teams
- regulators
Methods and Sources of Patient Input
- patient preference information/studies
Impact of Patient Engagement
- Quantitative methods can capture patient trade-offs: Quantitative patient-preference evidence enabled FDA reviewers to explicitly incorporate patients’ perspectives on benefits, risks, and treatment trade-offs into benefit-risk assessments.
- Informed clinical trial design and regulatory review: FDA reviewers used the tool to help establish minimum clinical effectiveness thresholds for weight-loss devices, guide interpretation of clinical trial results, and support premarket approval decisions.
- Captured variation in patient preferences: By quantifying differences in patient risk tolerance, the study demonstrated that some devices may provide acceptable benefit-risk profiles for subsets of patients, supporting more patient-centered regulatory evaluations.
- Established a model for future medical products: The study served as a proof of concept for incorporating quantitative patient-preference evidence into FDA decision-making and informed the development of FDA guidance on including patient-preference information in medical device submissions.
Lessons Learned
- Quantitative patient-preference methods can inform regulatory decisions: Structured preference studies can provide measurable evidence that complements clinical data in benefit-risk assessments.
- Patients value benefits and risks differently than other stakeholders: Patient perspectives on meaningful benefits and acceptable risks may differ from those of regulators and clinicians, making direct patient input important for regulatory evaluation.
- Account for heterogeneity in patient preferences: Measuring variation in risk tolerance can identify patient subgroups with different benefit-risk preferences, helping inform more patient-centered regulatory decisions.
- Design studies around regulatory questions: Selecting clinically meaningful attributes and developing study instruments in collaboration with regulatory reviewers helps ensure patient-preference data are relevant for decision-making.
- Use rigorous, validated study methods: Discrete-choice experiments, respondent education (such as risk tutorials), cognitive testing, and validation checks can improve the reliability and interpretability of patient-preference data.
- Patient-preference evidence has applications across the product life cycle: In this case, the findings informed clinical trial design, premarket benefit-risk assessments, and post- approval decision-making, demonstrating that patient-preference studies can support multiple stages of medical product development and evaluation.